Cargando…
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report
Autores principales: | Chiaretti, Sabina, Bonifacio, Massimiliano, Agrippino, Roberta, Giglio, Fabio, Annunziata, Mario, Curti, Antonio, Del Principe, Maria Ilaria, Salutari, Prassede, Sciumè, Mariarita, Delia, Mario, Armenio, Marco, Mancini, Valentina, Mulè, Antonino, Grimaldi, Francesco, Rege-Cambrin, Giovanna, Santoro, Lidia, Lussana, Federico, Chiusolo, Patrizia, Pasciolla, Crescenza, Scattolin, Anna Maria, Cerrano, Marco, Ciccone, Maria, Defina, Marzia, Forghieri, Fabio, Mazzone, Carla, Piccini, Matteo, Ferrara, Felicetto, Pizzolo, Giovanni, Foà, Robin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335088/ https://www.ncbi.nlm.nih.gov/pubmed/35443561 http://dx.doi.org/10.3324/haematol.2021.280289 |
Ejemplares similares
-
ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report
por: Chiaretti, Sabina, et al.
Publicado: (2021) -
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study
por: Dargenio, Michelina, et al.
Publicado: (2022) -
P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY
por: Annunziata, Mario, et al.
Publicado: (2023) -
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
por: Cerrano, Marco, et al.
Publicado: (2022) -
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2023)